NASDAQ:VBLTVascular Biogenics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vascular Biogenics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.29 +0.03 (+2.38 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$1.23Now: $1.29▼$1.2950-Day Range$1.14MA: $1.28▼$1.6352-Week Range$0.90Now: $1.29▼$1.64Volume484,731 shsAverage Volume906,824 shsMarket Capitalization$54.09 millionP/E RatioN/ADividend YieldN/ABeta0.86 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVascular Biogenics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.88, Vascular Biogenics has a potential upside of 200.4% from its current price of $1.29.Amount of Analyst CoverageVascular Biogenics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesVascular Biogenics has received 266 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVascular Biogenics has received 295 “underperform” votes. (Add your “underperform” vote.)Community SentimentVascular Biogenics has received 52.58% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote “Outperform” if you believe VBLT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVascular Biogenics does not currently pay a dividend.Dividend GrowthVascular Biogenics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vascular Biogenics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 3.12% of the stock of Vascular Biogenics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vascular Biogenics are expected to decrease in the coming year, from ($0.57) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vascular Biogenics is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vascular Biogenics is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVascular Biogenics has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBLT Previous SymbolNASDAQ:VBLX CUSIPN/A CIK1603207 Webwww.vblrx.com Phone972-8993-5000Debt Debt-to-Equity Ratio0.06 Current Ratio4.11 Quick Ratio4.11Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$560,000.00 Price / Sales96.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book1.29Profitability EPS (Most Recent Fiscal Year)($0.54) Net Income$-19,460,000.00 Net Margins-2,909.45% Return on Equity-53.61% Return on Assets-40.84%Miscellaneous Employees38 Outstanding Shares41,930,000Market Cap$54.09 million Next Earnings Date8/11/2020 (Estimated) OptionableOptionable NASDAQ:VBLT Rates by TradingView Receive VBLT News and Ratings via Email Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter. Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions How has Vascular Biogenics' stock been impacted by COVID-19 (Coronavirus)? Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VBLT shares have increased by 5.7% and is now trading at $1.29. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Vascular Biogenics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vascular Biogenics. When is Vascular Biogenics' next earnings date? Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Vascular Biogenics. How were Vascular Biogenics' earnings last quarter? Vascular Biogenics Ltd (NASDAQ:VBLT) issued its quarterly earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.02. The biopharmaceutical company earned $0.37 million during the quarter, compared to analysts' expectations of $0.19 million. Vascular Biogenics had a negative net margin of 2,909.45% and a negative return on equity of 53.61%. View Vascular Biogenics' earnings history. What price target have analysts set for VBLT? 5 Wall Street analysts have issued 1-year price objectives for Vascular Biogenics' shares. Their forecasts range from $2.50 to $5.00. On average, they expect Vascular Biogenics' stock price to reach $3.88 in the next year. This suggests a possible upside of 200.4% from the stock's current price. View analysts' price targets for Vascular Biogenics. Has Vascular Biogenics been receiving favorable news coverage? Media headlines about VBLT stock have been trending somewhat negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vascular Biogenics earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutVascular Biogenics. Are investors shorting Vascular Biogenics? Vascular Biogenics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 96,800 shares, an increase of 33.7% from the April 30th total of 72,400 shares. Based on an average daily volume of 191,300 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.4% of the company's stock are short sold. View Vascular Biogenics' Current Options Chain. Who are some of Vascular Biogenics' key competitors? Some companies that are related to Vascular Biogenics include Gemphire Therapeutics (GEMP), Kalvista Pharmaceuticals (KALV), Lexicon Pharmaceuticals (LXRX), Paratek Pharmaceuticals (PRTK), NuCana (NCNA), IVERIC bio (ISEE), Chimerix (CMRX), Aravive (ARAV), vTv Therapeutics (VTVT), Nature's Sunshine Products (NATR), Aduro BioTech (ADRO), Kindred Biosciences (KIN), NeuBase Therapeutics (NBSE), Avenue Therapeutics (ATXI) and TAIWAN LIPOSOME/S (TLC). View all competitors. What other stocks do shareholders of Vascular Biogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include Alibaba Group (BABA), Opko Health (OPK), SCYNEXIS (SCYX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), vTv Therapeutics (VTVT), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), T2 Biosystems (TTOO) and AEterna Zentaris (AEZS). Who are Vascular Biogenics' key executives? Vascular Biogenics' management team includes the following people: Prof. Dror Harats, CEO & Director (Age 63)Mr. Amos Ron, CFO & Company Sec. (Age 65)Dr. Erez Feige, VP of Bus. Operations (Age 46)Dr. Eyal Breitbart, VP of Research & Operations (Age 53)Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 66) What is Vascular Biogenics' stock symbol? Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT." Who are Vascular Biogenics' major shareholders? Vascular Biogenics' stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (1.05%), Advisor Group Holdings Inc. (0.12%) and Envestnet Asset Management Inc. (0.10%). Which institutional investors are buying Vascular Biogenics stock? VBLT stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Envestnet Asset Management Inc., and Morgan Stanley. How do I buy shares of Vascular Biogenics? Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vascular Biogenics' stock price today? One share of VBLT stock can currently be purchased for approximately $1.29. How big of a company is Vascular Biogenics? Vascular Biogenics has a market capitalization of $54.09 million and generates $560,000.00 in revenue each year. The biopharmaceutical company earns $-19,460,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Vascular Biogenics employs 38 workers across the globe. What is Vascular Biogenics' official website? The official website for Vascular Biogenics is www.vblrx.com. How can I contact Vascular Biogenics? Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
